TMCnet News
Syneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and RetentionMORRISVILLE, N.C. and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Ride Health to offer non-emergency medical transportation (NEMT) to clinical trial participants. The collaboration, built on product integration between Ride Health and the Syneos Health patient engagement platform, will enable a comprehensive transportation program for Syneos Health trials in the U.S., with a goal of expanding access, reducing burden and improving retention for patients while accelerating clinical trial recruitment for sponsors. Additionally, Syneos Health made a minority investment in Ride Health as part of the strategic relationship. The partnership reinforces the Syneos Health commitment to deliver patient-centric, technology-enabled solutions that improve the overall experience of clinical trials for sponsors, sites and patients. In 2020, Syneos Health acquired U.K.-based Illingworth Research Group (Illingworth), which included PatientGoTM, an in-house patient concierge service that aims to streamline clinical trial participation for patients through services ranging from ground and air transportation to overnight accommodation and expense reimbursements. Ride Health’s technology-enabled approach and deep integration capabilities help PatientGo to streamline and add new efficiencies to its U.S.-based transportation operations and accelerate network development to create a leading comprehensive clinical trial platform. Syneos Health and its trial sponsors have long recognized the benefit of transportation assistance to expand patient access, recruitment an retention. However, previous approaches created significant administrative burden for clinical trial coordinators and were often limited to a narrow selection of transportation providers relative to the scope of geographic and service level needs of enrolled patients. Ride Health’s national transportation network integrates ride-hailing services, taxi aggregators, and higher-touch NEMT operators to provide demand-responsive, cost-effective, and accessible transportation across a trial’s multi-state site footprint. To ensure consistent access to visits and prioritize patient centricity, the platform automatically matches each patient’s needs to the appropriate transportation mode across standard curbside pickup, door-to-door assistance, and wheelchair accessible vehicles. Ride Health’s solution then directly connects each stakeholder through its automated communication and support systems, allowing Syneos Health to reduce the coordination burden for site staff, enhance patient experience, and improve retention across clinical trials. “We are honored to partner with an industry leader like Syneos Health to enhance access to care, improve patient centricity and ensure clinical trial participation reflects the population that these novel therapeutics aim to serve,” said Imran Cronk, CEO and Founder of Ride Health. Ride Health’s HIPAA-compliant transportation solution is tailored for clinical trial management, streamlining coordination across trial sponsors, contract research organizations (CROs), independent research sites, and trial participants. The company’s transportation coordination platform ensures appropriate PHI (Protected Health Information) access across organizations, allowing each site to offer transportation while providing systems for CROs and trial sponsors to manage eligibility, utilization, and funding across all active trials. The web-based platform can be accessed directly on desktop or mobile devices, while a suite of open APIs (application programming interface) enable direct integration with existing clinical trial management systems and patient-facing applications. About Ride Health About Syneos Health To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
|